BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 8265981)

  • 21. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
    Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.
    Besana C; Borri A; Bucci E; Citterio G; Di Lucca G; Fortis C; Matteucci P; Tognella S; Tresoldi M; Baiocchi C
    Eur J Cancer; 1994; 30A(9):1292-8. PubMed ID: 7999416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy.
    Schomburg A; Kirchner H; Lopez-Hänninen E; Menzel T; Rudolph P; Körfer A; Fenner M; Poliwoda H; Atzpodien J
    Am J Clin Oncol; 1994 Jun; 17(3):199-209. PubMed ID: 7910716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma.
    Buzio C; Andrulli S; Santi R; Pavone L; Passalacqua R; Potenzoni D; Ferrozzi F; Giacosa R; Vaglio A
    Cancer; 2001 Nov; 92(9):2286-96. PubMed ID: 11745283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
    Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study.
    Facendola G; Locatelli MC; Pizzocaro G; Piva L; Pegoraro C; Pallavicini EB; Signaroldi A; Meregalli M; Lombardi F; Beretta GD
    Br J Cancer; 1995 Dec; 72(6):1531-5. PubMed ID: 8519672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.
    Farace F; Mathiot C; Brandely M; Tursz T; Dorval T; Pouillart P; Triebel F; Hercend T; Fridman WH
    Clin Exp Immunol; 1990 Nov; 82(2):194-9. PubMed ID: 2122928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
    Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
    Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.
    Morecki S; Revel-Vilk S; Nabet C; Pick M; Ackerstein A; Nagler A; Naparstek E; Ben Shahar M; Slavin S
    Cancer Immunol Immunother; 1992; 35(6):401-11. PubMed ID: 1394343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
    Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
    J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of recombinant human interleukin-2: biological features and clinical relevance.
    Hänninen EL; Knüver-Hopf J; Atzpodien J
    Biotherapy; 1993; 6(4):251-61. PubMed ID: 7517168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
    Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
    Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group.
    Queirolo P; Ponte M; Gipponi M; Cafiero F; Peressini A; Semino C; Pietra G; Lionetto R; Vecchio S; Ribizzi I; Melioli G; Sertoli MR
    Ann Surg Oncol; 1999; 6(3):272-8. PubMed ID: 10340886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
    Pichert G; Jost LM; Fierz W; Stahel RA
    Br J Cancer; 1991 Feb; 63(2):287-92. PubMed ID: 1997108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study.
    Bergmann L; Weidmann E; Mitrou PS; Runne U; Keilholz U; Bartsch HH; Franks CR
    Onkologie; 1990 Apr; 13(2):137-40. PubMed ID: 2197585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
    Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
    J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.